Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals
Jingxuan Quek, Cheng Han Ng, Ansel Shao Pin Tang, et al.
Endocrine Practice (2022) Vol. 28, Iss. 7, pp. 667-672
Closed Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

The global burden of metabolic disease: Data from 2000 to 2019
Nicholas Chew, Cheng Han Ng, Darren Jun Hao Tan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 3, pp. 414-428.e3
Closed Access | Times Cited: 377
Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals
Kai En Chan, Tiffany Jia Ling Koh, Ansel Shao Pin Tang, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 9, pp. 2691-2700
Open Access | Times Cited: 184
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 96
The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000–2019
Bryan Chong, Gwyneth Kong, Kannan Shankar, et al.
Metabolism (2023) Vol. 141, pp. 155402-155402
Open Access | Times Cited: 92
Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis
Ansel Shao Pin Tang, Cheng Han Ng, Poh Hui Phang, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 7, pp. 1750-1760.e12
Closed Access | Times Cited: 76
Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
Mohammad Habibullah, Khaleed Jemmieh, Amr Ouda, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 29
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus
Xufen Zeng, Krista A Varady, Xiangdong Wang, et al.
Metabolism (2024) Vol. 161, pp. 156028-156028
Closed Access | Times Cited: 20
MAFLD: Exploring the Systemic Effects Beyond Liver.
Utkarsh Dayal, Ujjwal Soni, Sourav Bansal, et al.
Journal of Community Hospital Internal Medicine Perspectives (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 790-801
Open Access | Times Cited: 55
Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
Sara Volpe, Giuseppe Lisco, Margherita Fanelli, et al.
Nutrients (2022) Vol. 14, Iss. 21, pp. 4673-4673
Open Access | Times Cited: 48
Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction
Amedeo Lonardo, Ashwani K. Singal, Natalia A. Osna, et al.
Metabolism and Target Organ Damage (2022) Vol. 2, pp. 12-12
Open Access | Times Cited: 41
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
Anders Mellemkjær, Mikkel Breinholt Kjær, David Haldrup, et al.
European Journal of Internal Medicine (2023) Vol. 122, pp. 28-34
Open Access | Times Cited: 34
Epicardial Adipose Tissue Assessed by Computed Tomography and Echocardiography Are Associated With Adverse Cardiovascular Outcomes: A Systematic Review and Meta-Analysis
Bryan Chong, Jayanth Jayabaskaran, Jitesh Ruban, et al.
Circulation Cardiovascular Imaging (2023) Vol. 16, Iss. 5
Closed Access | Times Cited: 29
Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China
Jingfeng Chen, Zhuo-Qing Wu, H. Liu, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 10, pp. 1346-1357
Open Access | Times Cited: 12
Association between cataract and fatty liver diseases from a nationwide cross-sectional study in South Korea
Kyoung Hae Kang, Daeun Chloe Shin, Ik Hee Ryu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
Yulino Castillo-Núñez, Paloma Almeda‐Valdés, Guillermo González-Gálvez, et al.
Current Diabetes Reports (2024) Vol. 24, Iss. 7, pp. 158-166
Closed Access | Times Cited: 9
Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study
Ana‐Lucia Mayén, Mirna Sabra, Elom K. Aglago, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease
Niki Katsiki, Genovefa Kolovou, Michal Vrablı́k
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Closed Access | Times Cited: 1
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
Mark Muthiah, Cheng Han Ng, Kai En Chan, et al.
Annals of Hepatology (2022) Vol. 28, Iss. 1, pp. 100762-100762
Open Access | Times Cited: 36
Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease
Jeong‐Ju Yoo, Man Young Park, Eun Ju Cho, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3336-3336
Open Access | Times Cited: 16
Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Maria Principia Scavo, Giuseppe Lisco, Nicoletta Depalo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1493-1493
Open Access | Times Cited: 6
The Spectrum and Impact of Metabolic Dysfunction in MAFLD: A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals
Kai En Chan, Cheng Han Ng, Clarissa Elysia Fu, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 10, pp. 2560-2569.e15
Closed Access | Times Cited: 25
The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer
Suosu Wei, Yanrong Hao, Xiaofeng Dong, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 15
Socioeconomic deprivation and prognostic outcomes in acute coronary syndrome: A meta-analysis using multidimensional socioeconomic status indices
Vickram Vijay Anand, Ethan Lee Cheng Zhe, Yip Han Chin, et al.
International Journal of Cardiology (2023) Vol. 383, pp. 140-150
Closed Access | Times Cited: 13
Bromoxynil induced hepatic toxicity via dysregulating TLR4/MyD88, JAK1/STAT3 and NF-κB signaling pathways: A dose-dependent investigation
Khalid J. Alzahrani, Mahmoud El Safadi, Fuad M. Alzahrani, et al.
Tissue and Cell (2025) Vol. 93, pp. 102735-102735
Closed Access
Page 1 - Next Page

Scroll to top